Dolby Laboratories (NYSE: DLB ) reported earnings on Aug. 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 29 (Q3), Dolby Laboratories missed estimates on revenue and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share shrank.
Gross margins increased, operating margins contracted, and net margins shrank.
Dolby Laboratories chalked up revenue of $207.9 million. The nine analysts polled by S&P Capital IQ predicted revenue of $218.3 million on the same basis. GAAP reported sales were 5.1% lower than the prior-year quarter's $219.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.57. The six earnings estimates compiled by S&P Capital IQ averaged $0.58 per share. GAAP EPS of $0.48 for Q3 were 13% lower than the prior-year quarter's $0.55 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 89.9%, 270 basis points better than the prior-year quarter. Operating margin was 32.7%, 740 basis points worse than the prior-year quarter. Net margin was 24.8%, 340 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $231.3 million. On the bottom line, the average EPS estimate is $0.66.
Next year's average estimate for revenue is $941.3 million. The average EPS estimate is $2.83.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 3,962 members out of 4,057 rating the stock outperform, and 95 members rating it underperform. Among 998 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 980 give Dolby Laboratories a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dolby Laboratories is hold, with an average price target of $48.14.
- Add Dolby Laboratories to My Watchlist.